GLP-1-Based Therapies Have No Microvascular Effects in Type 2 Diabetes Mellitus: An Acute and 12-Week Randomized, Double-Blind, Placebo-Controlled Trial.
about
A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes.A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation.Highlighting Diabetes Mellitus: The Epidemic Continues.Diabetes, cardiovascular disease and the microcirculation.
P2860
GLP-1-Based Therapies Have No Microvascular Effects in Type 2 Diabetes Mellitus: An Acute and 12-Week Randomized, Double-Blind, Placebo-Controlled Trial.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
GLP-1-Based Therapies Have No ...... ind, Placebo-Controlled Trial.
@ast
GLP-1-Based Therapies Have No ...... ind, Placebo-Controlled Trial.
@en
type
label
GLP-1-Based Therapies Have No ...... ind, Placebo-Controlled Trial.
@ast
GLP-1-Based Therapies Have No ...... ind, Placebo-Controlled Trial.
@en
prefLabel
GLP-1-Based Therapies Have No ...... ind, Placebo-Controlled Trial.
@ast
GLP-1-Based Therapies Have No ...... ind, Placebo-Controlled Trial.
@en
P2093
P1476
GLP-1-Based Therapies Have No ...... ind, Placebo-Controlled Trial.
@en
P2093
Daniël H van Raalte
Erik H Serné
Lennart Tonneijck
Marcel H A Muskiet
Mark H H Kramer
Michaela Diamant
P304
P356
10.1161/ATVBAHA.116.307930
P407
P577
2016-08-25T00:00:00Z